Journal Article

T-Cell Engagers — Modern Immune-Based Therapies for Multiple Myeloma

  • Mailankody S
  • Landgren O
New England Journal of Medicine (2022) 387(6) 558-561
DOI: 10.1056/nejme2209692
12Citations
Citations of this article
37Readers
Mendeley users who have this article in their library.
Get full text

Abstract

B-cell maturation antigen (BCMA) was identified as a prognostic marker in multiple myeloma more than two decades ago. Starting in 2014, the first use of BCMA as a treatment target was evaluated in ...

Cite

CITATION STYLE

APA

Mailankody, S., & Landgren, O. (2022). T-Cell Engagers — Modern Immune-Based Therapies for Multiple Myeloma. New England Journal of Medicine, 387(6), 558–561. https://doi.org/10.1056/nejme2209692

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free